Weiss Ratings Reaffirms Sell (E+) Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating reiterated by Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Tuesday, February 25th.

60 Degrees Pharmaceuticals Stock Performance

SXTP opened at $1.77 on Friday. The firm’s 50-day simple moving average is $2.86 and its 200-day simple moving average is $4.78. 60 Degrees Pharmaceuticals has a twelve month low of $1.41 and a twelve month high of $35.99. The firm has a market cap of $2.61 million, a price-to-earnings ratio of -0.18 and a beta of 4.52.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.